Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,982
archived clinical trials in
Endocrine

Reduction of Nocturnal Hypoglycemia and Hyperglycemia in the Home Using Predictive Algorithms, Pump Suspension, and Insulin Dosing in Children and Young Adolescents
Reduction of Nocturnal Hypoglycemia and Hyperglycemia in the Home Using Predictive Algorithms, Pump Suspension, and Insulin Dosing in Children and Young Adolescents (PHM3)
Status: Enrolling
Updated:  5/9/2017
Barbara Davis Center for Childhood Diabetes
mi
from
Aurora, CO
Reduction of Nocturnal Hypoglycemia and Hyperglycemia in the Home Using Predictive Algorithms, Pump Suspension, and Insulin Dosing in Children and Young Adolescents
Reduction of Nocturnal Hypoglycemia and Hyperglycemia in the Home Using Predictive Algorithms, Pump Suspension, and Insulin Dosing in Children and Young Adolescents (PHM3)
Status: Enrolling
Updated: 5/9/2017
Barbara Davis Center for Childhood Diabetes
mi
from
Aurora, CO
Click here to add this to my saved trials
Determine How Consumption of Dairy Fat as Cheese Influences Inflammation-Phase 2
Effects of Dairy Fat on Postprandial Inflammation- Phase 2
Status: Enrolling
Updated:  5/18/2017
USDA-Western Human Nutrition Research Center
mi
from
Davis, CA
Determine How Consumption of Dairy Fat as Cheese Influences Inflammation-Phase 2
Effects of Dairy Fat on Postprandial Inflammation- Phase 2
Status: Enrolling
Updated: 5/18/2017
USDA-Western Human Nutrition Research Center
mi
from
Davis, CA
Click here to add this to my saved trials
Determine How Consumption of Dairy Fat Fractions Rich in Phospholipids and Proteins Influence Inflammation in the Fed State-Phase 1
Effects of Dairy Fat on Postprandial Inflammation- Phase 2
Status: Enrolling
Updated:  5/18/2017
USDA-Western Human Nutrition Research Center
mi
from
Davis, CA
Determine How Consumption of Dairy Fat Fractions Rich in Phospholipids and Proteins Influence Inflammation in the Fed State-Phase 1
Effects of Dairy Fat on Postprandial Inflammation- Phase 2
Status: Enrolling
Updated: 5/18/2017
USDA-Western Human Nutrition Research Center
mi
from
Davis, CA
Click here to add this to my saved trials
28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men
A Phase II, 28-Day, Randomized, Parallel-Group, Open-Label Study Evaluating the Efficacy and Safety of Twice Daily Oral Doses of Testosterone (150-400mg) Co-administered With 0.25mg Dutasteride Compared With 400mg Testosterone Alone and 0.25mg Dutasteride Alone in the Treatment of Hypogonadism
Status: Enrolling
Updated:  5/25/2017
GSK Investigational Site
mi
from
Torrance, CA
28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men
A Phase II, 28-Day, Randomized, Parallel-Group, Open-Label Study Evaluating the Efficacy and Safety of Twice Daily Oral Doses of Testosterone (150-400mg) Co-administered With 0.25mg Dutasteride Compared With 400mg Testosterone Alone and 0.25mg Dutasteride Alone in the Treatment of Hypogonadism
Status: Enrolling
Updated: 5/25/2017
GSK Investigational Site
mi
from
Torrance, CA
Click here to add this to my saved trials
28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men
A Phase II, 28-Day, Randomized, Parallel-Group, Open-Label Study Evaluating the Efficacy and Safety of Twice Daily Oral Doses of Testosterone (150-400mg) Co-administered With 0.25mg Dutasteride Compared With 400mg Testosterone Alone and 0.25mg Dutasteride Alone in the Treatment of Hypogonadism
Status: Enrolling
Updated:  5/25/2017
GSK Investigational Site
mi
from
Louisville, KY
28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men
A Phase II, 28-Day, Randomized, Parallel-Group, Open-Label Study Evaluating the Efficacy and Safety of Twice Daily Oral Doses of Testosterone (150-400mg) Co-administered With 0.25mg Dutasteride Compared With 400mg Testosterone Alone and 0.25mg Dutasteride Alone in the Treatment of Hypogonadism
Status: Enrolling
Updated: 5/25/2017
GSK Investigational Site
mi
from
Louisville, KY
Click here to add this to my saved trials
28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men
A Phase II, 28-Day, Randomized, Parallel-Group, Open-Label Study Evaluating the Efficacy and Safety of Twice Daily Oral Doses of Testosterone (150-400mg) Co-administered With 0.25mg Dutasteride Compared With 400mg Testosterone Alone and 0.25mg Dutasteride Alone in the Treatment of Hypogonadism
Status: Enrolling
Updated:  5/25/2017
GSK Investigational Site
mi
from
Baltimore, MD
28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men
A Phase II, 28-Day, Randomized, Parallel-Group, Open-Label Study Evaluating the Efficacy and Safety of Twice Daily Oral Doses of Testosterone (150-400mg) Co-administered With 0.25mg Dutasteride Compared With 400mg Testosterone Alone and 0.25mg Dutasteride Alone in the Treatment of Hypogonadism
Status: Enrolling
Updated: 5/25/2017
GSK Investigational Site
mi
from
Baltimore, MD
Click here to add this to my saved trials
28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men
A Phase II, 28-Day, Randomized, Parallel-Group, Open-Label Study Evaluating the Efficacy and Safety of Twice Daily Oral Doses of Testosterone (150-400mg) Co-administered With 0.25mg Dutasteride Compared With 400mg Testosterone Alone and 0.25mg Dutasteride Alone in the Treatment of Hypogonadism
Status: Enrolling
Updated:  5/25/2017
GSK Investigational Site
mi
from
Durham, NC
28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men
A Phase II, 28-Day, Randomized, Parallel-Group, Open-Label Study Evaluating the Efficacy and Safety of Twice Daily Oral Doses of Testosterone (150-400mg) Co-administered With 0.25mg Dutasteride Compared With 400mg Testosterone Alone and 0.25mg Dutasteride Alone in the Treatment of Hypogonadism
Status: Enrolling
Updated: 5/25/2017
GSK Investigational Site
mi
from
Durham, NC
Click here to add this to my saved trials
28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men
A Phase II, 28-Day, Randomized, Parallel-Group, Open-Label Study Evaluating the Efficacy and Safety of Twice Daily Oral Doses of Testosterone (150-400mg) Co-administered With 0.25mg Dutasteride Compared With 400mg Testosterone Alone and 0.25mg Dutasteride Alone in the Treatment of Hypogonadism
Status: Enrolling
Updated:  5/25/2017
GSK Investigational Site
mi
from
San Antonio, TX
28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men
A Phase II, 28-Day, Randomized, Parallel-Group, Open-Label Study Evaluating the Efficacy and Safety of Twice Daily Oral Doses of Testosterone (150-400mg) Co-administered With 0.25mg Dutasteride Compared With 400mg Testosterone Alone and 0.25mg Dutasteride Alone in the Treatment of Hypogonadism
Status: Enrolling
Updated: 5/25/2017
GSK Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men
A Phase II, 28-Day, Randomized, Parallel-Group, Open-Label Study Evaluating the Efficacy and Safety of Twice Daily Oral Doses of Testosterone (150-400mg) Co-administered With 0.25mg Dutasteride Compared With 400mg Testosterone Alone and 0.25mg Dutasteride Alone in the Treatment of Hypogonadism
Status: Enrolling
Updated:  5/25/2017
GSK Investigational Site
mi
from
Seattle, WA
28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men
A Phase II, 28-Day, Randomized, Parallel-Group, Open-Label Study Evaluating the Efficacy and Safety of Twice Daily Oral Doses of Testosterone (150-400mg) Co-administered With 0.25mg Dutasteride Compared With 400mg Testosterone Alone and 0.25mg Dutasteride Alone in the Treatment of Hypogonadism
Status: Enrolling
Updated: 5/25/2017
GSK Investigational Site
mi
from
Seattle, WA
Click here to add this to my saved trials
Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism
A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Tolerability of Single Ascending Doses of KAI-4169 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  5/26/2017
Clinical Research Facility
mi
from
Cypress, CA
Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism
A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Tolerability of Single Ascending Doses of KAI-4169 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 5/26/2017
Clinical Research Facility
mi
from
Cypress, CA
Click here to add this to my saved trials
Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism
A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Tolerability of Single Ascending Doses of KAI-4169 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  5/26/2017
Clinical Research Facility
mi
from
Shreveport, LA
Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism
A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Tolerability of Single Ascending Doses of KAI-4169 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 5/26/2017
Clinical Research Facility
mi
from
Shreveport, LA
Click here to add this to my saved trials
Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism
A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Tolerability of Single Ascending Doses of KAI-4169 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  5/26/2017
Clinical Research Facility
mi
from
Houston, TX
Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism
A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Tolerability of Single Ascending Doses of KAI-4169 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 5/26/2017
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism
A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Tolerability of Single Ascending Doses of KAI-4169 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  5/26/2017
mi
from
Brisbane,
Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism
A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Tolerability of Single Ascending Doses of KAI-4169 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 5/26/2017
mi
from
Brisbane,
Click here to add this to my saved trials
Meal Patterning on Weight Loss With Changes to Body Comp, Muscle and Metabolic Health
Effects of Dietary Protein Patterning on wt Loss and Resistance Training-induced Changes in Body Comp, Skeletal Muscle, and Indices of Metabolic Syndrome
Status: Enrolling
Updated:  5/31/2017
Purdue University
mi
from
West Lafayette, IN
Meal Patterning on Weight Loss With Changes to Body Comp, Muscle and Metabolic Health
Effects of Dietary Protein Patterning on wt Loss and Resistance Training-induced Changes in Body Comp, Skeletal Muscle, and Indices of Metabolic Syndrome
Status: Enrolling
Updated: 5/31/2017
Purdue University
mi
from
West Lafayette, IN
Click here to add this to my saved trials
Effects of Omega-3 Fatty Acids on Markers of Inflammation
Effects of Plant and Marine Omega-3 (w-3) Fatty Acids on Inflammatory Markers In Insulin Resistant Adults
Status: Enrolling
Updated:  5/31/2017
Stanford University School of Medicine
mi
from
Stanford, CA
Effects of Omega-3 Fatty Acids on Markers of Inflammation
Effects of Plant and Marine Omega-3 (w-3) Fatty Acids on Inflammatory Markers In Insulin Resistant Adults
Status: Enrolling
Updated: 5/31/2017
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Thyroid Disease Serum Repository
Thyroid Disease Serum Repository
Status: Enrolling
Updated:  6/1/2017
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Thyroid Disease Serum Repository
Thyroid Disease Serum Repository
Status: Enrolling
Updated: 6/1/2017
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
Effects and Mechanisms of Melatonin on Blood Pressure, Insulin Resistance, and Platelets
Effects and Mechanisms of Melatonin on Blood Pressure, Insulin Resistance, and Platelets
Status: Enrolling
Updated:  6/5/2017
Thomas Jefferson University
mi
from
Philadelphia, PA
Effects and Mechanisms of Melatonin on Blood Pressure, Insulin Resistance, and Platelets
Effects and Mechanisms of Melatonin on Blood Pressure, Insulin Resistance, and Platelets
Status: Enrolling
Updated: 6/5/2017
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Obstructive Sleep Apnea and Metabolic Health
Obstrutive Sleep Apnea: is it a Biomarker of Metabolically Healthy vs. Unhealthy Obese
Status: Enrolling
Updated:  6/6/2017
Ohio State University
mi
from
Columbus, OH
Obstructive Sleep Apnea and Metabolic Health
Obstrutive Sleep Apnea: is it a Biomarker of Metabolically Healthy vs. Unhealthy Obese
Status: Enrolling
Updated: 6/6/2017
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Weight Loss Diet Study: Low Carb vs Low Fat
Weight Loss Diet Study: Low Carbohydrate vs. Low Fat and Insulin Resistance Status
Status: Enrolling
Updated:  6/7/2017
Stanford University School of Medicine
mi
from
Stanford, CA
Weight Loss Diet Study: Low Carb vs Low Fat
Weight Loss Diet Study: Low Carbohydrate vs. Low Fat and Insulin Resistance Status
Status: Enrolling
Updated: 6/7/2017
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
The Metabolic Effects of Short-term Walnut Consumption in Subjects With the Metabolic Syndrome
The Metabolic Effects of Short-term Walnut Consumption in Subjects With the Metabolic Syndrome
Status: Enrolling
Updated:  6/21/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
The Metabolic Effects of Short-term Walnut Consumption in Subjects With the Metabolic Syndrome
The Metabolic Effects of Short-term Walnut Consumption in Subjects With the Metabolic Syndrome
Status: Enrolling
Updated: 6/21/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Effect of a Grape Seed Extract (GSE) on Insulin Resistance
Effect of a Grape Seed Extract (GSE) on Insulin Resistance
Status: Enrolling
Updated:  6/26/2017
VA Hospital, Mather
mi
from
Mather, CA
Effect of a Grape Seed Extract (GSE) on Insulin Resistance
Effect of a Grape Seed Extract (GSE) on Insulin Resistance
Status: Enrolling
Updated: 6/26/2017
VA Hospital, Mather
mi
from
Mather, CA
Click here to add this to my saved trials
Insulin Resistance in Nonalcoholic Fatty Liver Disease: A Case Control Study
Insulin Resistance in Nonalcoholic Fatty Liver Disease: A Case Control Study
Status: Enrolling
Updated:  7/10/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Insulin Resistance in Nonalcoholic Fatty Liver Disease: A Case Control Study
Insulin Resistance in Nonalcoholic Fatty Liver Disease: A Case Control Study
Status: Enrolling
Updated: 7/10/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
Clinical Research Facility
mi
from
Birmingham, AL
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
Clinical Research Facility
mi
from
Alhambra, CA
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
mi
from
Alhambra, CA
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
Clinical Research Facility
mi
from
Azusa, CA
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
mi
from
Azusa, CA
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
Clinical Research Facility
mi
from
Bakersfield, CA
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
mi
from
Bakersfield, CA
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
Clinical Research Facility
mi
from
Cudahy, CA
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
mi
from
Cudahy, CA
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
Clinical Research Facility
mi
from
Granada Hills, CA
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
mi
from
Granada Hills, CA
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
Clinical Research Facility
mi
from
Los Angeles, CA
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
Clinical Research Facility
mi
from
Los Angeles, CA
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
Clinical Research Facility
mi
from
Northridge, CA
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
mi
from
Northridge, CA
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
Clinical Research Facility
mi
from
Riverside, CA
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
mi
from
Riverside, CA
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
Clinical Research Facility
mi
from
Simi Valley, CA
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
mi
from
Simi Valley, CA
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
Clinical Research Facility
mi
from
Vacaville, CA
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
mi
from
Vacaville, CA
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
Clinical Research Facility
mi
from
Whittier, CA
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
mi
from
Whittier, CA
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
Clinical Research Facility
mi
from
Aurora, CO
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
Clinical Research Facility
mi
from
Westminster, CO
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
mi
from
Westminster, CO
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
Clinical Research Facility
mi
from
Stamford, CT
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
mi
from
Stamford, CT
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
Clinical Research Facility
mi
from
Miami, FL
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
Clinical Research Facility
mi
from
Ocala, FL
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
mi
from
Ocala, FL
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
Clinical Research Facility
mi
from
Pembroke Pines, FL
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
mi
from
Pembroke Pines, FL
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
Clinical Research Facility
mi
from
Tampa, FL
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
Clinical Research Facility
mi
from
Augusta, GA
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
mi
from
Augusta, GA
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
Clinical Research Facility
mi
from
Dublin, GA
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
mi
from
Dublin, GA
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
Clinical Research Facility
mi
from
Meridian, ID
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
mi
from
Meridian, ID
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
Clinical Research Facility
mi
from
Highland Park, IL
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
mi
from
Highland Park, IL
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
Clinical Research Facility
mi
from
Merrillville, IN
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
mi
from
Merrillville, IN
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
Clinical Research Facility
mi
from
Michigan City, IN
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
mi
from
Michigan City, IN
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
Clinical Research Facility
mi
from
Wichita, KA
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
mi
from
Wichita, KA
Click here to add this to my saved trials
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated:  7/11/2017
Clinical Research Facility
mi
from
Baton Rouge, LA
To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Status: Enrolling
Updated: 7/11/2017
Clinical Research Facility
mi
from
Baton Rouge, LA
Click here to add this to my saved trials